Cargando…
Adjuvant tamoxifen for male breast cancer (MBC).
A study was started in 1976 whereby patients with Stage II and operable Stage III MBC were given adjuvant Tamoxifen for 1 year, increasing to 2 years from 1988. All patients had axillary nodal involvement. Primary treatment consisted of a radical mastectomy or simple mastectomy with radiotherapy. Th...
Autores principales: | Ribeiro, G., Swindell, R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977740/ https://www.ncbi.nlm.nih.gov/pubmed/1739625 |
Ejemplares similares
-
The Christie hospital adjuvant tamoxifen trial--status at 10 years.
por: Ribeiro, G., et al.
Publicado: (1988) -
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
por: Gampenrieder, Simon Peter, et al.
Publicado: (2021) -
Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988) -
A Prognostic Analysis of Male Breast Cancer (MBC) Compared with Post-Menopausal Female Breast Cancer (FBC)
por: Yu, Xing-Fei, et al.
Publicado: (2015) -
Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404
por: Shien, Tadahiko, et al.
Publicado: (2014)